Evaluation of pharmacokinetic and safety profiles in patients with pulmonary NTM disease, suggesting effective targeting.
Background: Oral administration of clofazimine, an antimicrobial agent with demonstrated in vitro efficacy against nontuberculous mycobacteria (NTM), including Mycobacterium avium complex, requires high dosages to reach minimum inhibitory concentration in the lungs. Clofazimine Inhalation Suspension is a novel formulation designed to offer rapid, targeted drug delivery with prolonged half-life in lung tissues while minimizing systemic toxicities. The objective of this study was to evaluate the pharmacokinetic and safety profiles and proposed dosing regimen of Clofazimine Inhalation Suspension for adjuvant treatment of pulmonary NTM disease.
No takes yet. Share an insight, caveat, or question.
Fares et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: